

NeoPhore

Mismatch repair drugs for cancer immunotherapy



Company summary

Early stage small molecule immuno-oncology company focused on neoantigen generation through targeting DNA mismatch repair pathways:


- Launched Nov 2017: £4M venture & grant funding
- Sixth Element Capital
- Founded with headquarters in Cambridge, UK
- Capitalised into 2020: seeking partners and additional financing in fall 2019
- Executive team, advisor network and full operational capabilities
- Committed academic KOLs and founder partners

Mismatch repair & cancer neoantigens: at the core of cancer immunotherapy

Adapted from Jaffe and colleagues, 2017



The NEW ENGLAND
JOURNAL of MEDICINE



NeoPhore team

Executive Management

- All staff with 15yrs + drug discovery experience each
- Entrepreneur scientists with strong research reputation

VP Drug Discovery
Julian Blagg



VP Immunology
Matthew Baker



Director, Chemistry
Jon Roffey



Board

- Lead venture investor: dedicated cancer therapeutics fund
- Founder CEOs, CSOs and deep commercial track-record

CEO
Jeff Roix



Chairman
Rob James, 6th Element



Independent
John Haurum (F-Star, Symphogen)



Chris Torrance
Founder: PhoreMost, NeoPhore &
Horizon Discovery



Ian Miscampbell
6th Element Capital




Steven Myatt
6th Element Capital



Scientific Advisors

- Cancer research innovators, influential clinicians
- High-impact founding science from top institutes

Alberto Bardelli (Univ. of Turin)
Founder: NeoPhore & Horizon Discovery plc



Luis Diaz (MSKCC)



Bert Vogelstein (JHMI)




Rick Fishel (OSU)



**Cancer
Immunology,
Chemistry**


MMR portfolio:

Progressing a lead and backup programme into 2020



A backbone combination agent for immunotherapy:

Enhancing neoantigen creation and intrinsic cancer immunogenicity across indications and modalities



Company highlights

Mismatch Repair

Inhibitors:

NeoPhore Assets



Product Pipeline

MMR #1

- First-in-class MMR inhibitor
- Lead series and diverse hit chemistry
- Crystallographic insights
- Pharmacology: enzyme, cell and animals

MMR #2

- Back-up screening on 2nd MMR target
- Discrete chemistry & pharmacology
- Target validation and biomarker know-how

Product Profile

- Small-molecule combination agents for cancer immunotherapy
- Validation in combo with PD1: clinical proof and preclinical PoC
- Cancer-type agnostic: proven across diverse “cold” disease types
- Immune cell agnostic: stimulates neoantigens & broader effector-pathways